Fortis Healthcare Q4 FY26 Results Analysis: PAT Surges 44.6%, EBITDA Margin Expands 214 bps
Fortis Healthcare Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 2,364.67 Cr (+17.84% YoY) and PAT growth of +44.58% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | May 22, 2026 |
|---|---|
| Quarter | Q4 FY 2025-2026 |
| Revenue (Q4) | Rs. 2,364.67 Cr (+17.84% YoY) |
| PAT (Q4) | Rs. 271.19 Cr (+44.58% YoY) |
| EBITDA margin | 22.70% (+214 bps YoY) |
| EPS (Q4) | Rs. 3.52 (+44.26% YoY) |
| Market cap | Rs. 72,630.64 Cr |
| CMP | Rs. 961.80 |
Quarter Snapshot
Consolidated revenue grew 17.8% YoY, PAT surged 44.6% YoY, and FY26 EBITDA margin expanded 214 bps to 23.40% from operating leverage. Diagnostics margin nearly doubled, but finance costs rose 70% from acquisition debt and occupancy remains below target, with key legal overhang pending September 2026.
Key Investment Insights
Key Positives
- Consolidated PAT attributable to owners grew 44.58% YoY to Rs.26,585 Lakh in Q4 FY26.
- FY26 EBITDA margin expanded 214 bps to 23.40%, driven by total expenses growing slower than revenue.
- Diagnostics segment EBIT margin expanded 649 bps YoY to 15.84% in FY26.
- Healthcare segment EBIT grew 30.13% YoY in FY26 to Rs.139,370 Lakh with margin expansion of 180 bps.
- Operating cash flow was 150% of PAT, indicating high earnings quality.
- Credit rating upgraded by CRISIL from AA to AA+ (Stable).
Risk Factors
- Occupancy declined to 67% in Q3 FY26 due to new facility ramp-up; Q4 occupancy data not disclosed.
- Current ratio at 0.86x indicates working capital pressure from rapid expansion.
- Tax disputes total Rs.266 Cr (demands for AY 2021-22 and AY 2024-25); company evaluating appeals.
- Legal uncertainty from NTK vs Daiichi Sankyo judgment due September 10, 2026.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.